山东泰泽惠康生物医药

Taize Huikang is a clinical-stage biotechnology company based in Jinan, China, dedicated to the development of innovative peptide therapeutics for metabolic diseases. The company leverages a proprietary technology platform to engineer multi-target agonists, including dual and triple receptor agonists targeting GLP-1, GIP, and glucagon receptors. Its lead candidate, TH-007, is a long-acting triple agonist currently in Phase 1 clinical trials for the treatment of obesity and type 2 diabetes. Beyond its lead program, the company is advancing a pipeline of dual agonists and biosimilars aimed at addressing the global metabolic health crisis. Taize Huikang integrates research, development, and pilot manufacturing to accelerate the delivery of high-potency peptide drugs to the market.